A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma

INTRODUCTION: A combination of cetuximab and sorafenib in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) were assessed for potential benefit. MATERIAL AND METHODS: In a randomized phase II study, R/M HNSCC patients were treated with cetuximab 400mg/m(2)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Gilbert, Jill, Schell, Michael J., Zhao, Xiuhua, Murphy, Barbara, Tanvetyanon, Tawee, Leon, Marino E., Hayes, D. Neil, Haigentz, Missak, Saba, Nabil, Nieva, Jorge, Bishop, Justin, Sidransky, David, Ravi, Rajani, Bedi, Atul, Chung, Christine H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459134/
https://ncbi.nlm.nih.gov/pubmed/25593015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2014.12.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados